S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
AMD Results Are No Reason To Buy Semiconductors... Yet
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
Positive News Sentiment  
NASDAQ:XXII

22nd Century Group - XXII Stock Forecast, Price & News

$1.07
-0.03 (-2.73%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.04
▼
$1.10
50-Day Range
$0.82
▼
$1.21
52-Week Range
$0.82
▼
$2.71
Volume
1.24 million shs
Average Volume
1.08 million shs
Market Capitalization
$230.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

22nd Century Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
367.3% Upside
$5.00 Price Target
Short Interest
Bearish
7.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.24) to ($0.21) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Consumer Staples Sector

105th out of 140 stocks

Cigarettes Industry

4th out of 5 stocks

See Top Rated MarketRank™ Stocks Here

XXII stock logo

About 22nd Century Group (NASDAQ:XXII) Stock

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Receive XXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 22nd Century Group and its competitors with MarketBeat's FREE daily newsletter.

XXII Stock News Headlines

January 23, 2023 | finance.yahoo.com
22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
January 18, 2023 | finance.yahoo.com
22nd Century Group (XXII) Announces U.S. Distribution Partnerships with Core-Mark and Eby-Brown
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 17, 2023 | finance.yahoo.com
FDA's Proposed Menthol Ban Advances to Final Rule Status, Greatly Benefits 22nd Century (XXII) by Affirming the Need for VLN(R) Menthol King as a Critical Off-Ramp for Adult Menthol Smokers
December 28, 2022 | msn.com
12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
December 13, 2022 | finance.yahoo.com
22nd Century Group (XXII) Comments on the Advancement of New Zealand's National Reduced Nicotine Content Law
December 8, 2022 | finance.yahoo.com
22nd Century Group Provides Update on Grass Valley Facility
December 5, 2022 | msn.com
22nd Century Group Earnings Perspective: Return On Capital Employed
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
November 21, 2022 | finance.yahoo.com
22nd Century Group Provides Update on Incident at Grass Valley Facility
November 17, 2022 | finance.yahoo.com
22nd Century Group had a big year. The FDA could make 2023 even bigger.
November 16, 2022 | seekingalpha.com
22nd Century Group Could Turn Profitable In 2023
November 15, 2022 | finance.yahoo.com
22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas
November 9, 2022 | seekingalpha.com
22nd Century Group, Inc. (XXII) Q3 2022 Earnings Call Transcript
November 8, 2022 | benzinga.com
22nd Century Group Q3 Revenue Grows 148% YoY, Here Are The Details
November 8, 2022 | finance.yahoo.com
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Third Quarter 2022
November 7, 2022 | technews.tmcnet.com
New Study Again Shows 22nd Century's Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking Cessation
November 7, 2022 | finance.yahoo.com
New Study Again Shows 22nd Century’s Reduced Nicotine Content Cigarettes Reduce Cigarette Consumption and Increase Smoking Cessation
October 27, 2022 | finance.yahoo.com
22nd Century Group (Nasdaq: XXII) to Announce Third Quarter 2022 Results on November 8, 2022
October 26, 2022 | finance.yahoo.com
22nd Century Group (Nasdaq: XXII) to Expand VLN® Sales in Three Additional States: Arizona, Utah and New Mexico
October 18, 2022 | finance.yahoo.com
22nd Century Group (Nasdaq: XXII) to Present at LD Micro Conference on October 26
October 16, 2022 | marketwatch.com
Thinking about buying stock in Imara, Nutanix, Azul, 22nd Century Group, or Altimmune?
October 6, 2022 | finance.yahoo.com
First Cigarette Authorized by FDA to “Help You Smoke Less” Now Available Across Colorado
October 5, 2022 | marketwatch.com
22nd Century Group (Nasdaq: XXII) Expands VLN(R) Distributor Network with the Addition of Specialty Distributor Creager Mercantile
October 3, 2022 | finance.yahoo.com
22nd Century Group (Nasdaq: XXII) Expands VLN® Distributor Network with the Addition of Specialty Distributor Creager Mercantile
September 20, 2022 | finance.yahoo.com
22nd Century Group (Nasdaq: XXII) Partners With Eagle Rock Distributing Company to Place VLN® in Thousands of Retail Locations Across Colorado
September 13, 2022 | technews.tmcnet.com
22nd Century Group's (Nasdaq: XXII) VLN® Cigarettes with Reduced Nicotine Technology Ready to Ignite Biden's Cancer Moonshot Initiative
See More Headlines
Receive XXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 22nd Century Group and its competitors with MarketBeat's FREE daily newsletter.

XXII Company Calendar

Last Earnings
11/08/2022
Today
2/01/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Cigarettes
Sub-Industry
Cannabis
Sector
Consumer Staples
Current Symbol
NASDAQ:XXII
Previous Symbol
AMEX:XXII
CUSIP
N/A
CIK
1347858
Web
www.xxiicentury.com
Phone
(716) 270-1523
Fax
716-877-3064
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+367.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,610,000.00
Net Margins
-93.35%
Pretax Margin
-98.40%
Return on Equity
-49.37%
Return on Assets
-42.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.45
Quick Ratio
2.79

Sales & Book Value

Annual Sales
$30.95 million
Price / Sales
7.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
2.61

Miscellaneous

Outstanding Shares
215,300,000
Free Float
210,135,000
Market Cap
$230.37 million
Optionable
Optionable
Beta
1.87

Key Executives

  • James A MishJames A Mish
    President, Chief Executive Officer & Director
  • John J. Miller
    Chief Operating Officer & President-Tobacco
  • Robert Hugh Kinsman
    Chief Financial Officer
  • Juan Sanchez Tamburrino
    Vice President-Research & Development
  • Calvin Treat
    Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













XXII Stock - Frequently Asked Questions

Should I buy or sell 22nd Century Group stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XXII shares.
View XXII analyst ratings or view top-rated stocks.

What is 22nd Century Group's stock price forecast for 2023?

3 analysts have issued twelve-month price objectives for 22nd Century Group's stock. Their XXII share price forecasts range from $4.00 to $6.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 367.3% from the stock's current price.
View analysts price targets for XXII or view top-rated stocks among Wall Street analysts.

How have XXII shares performed in 2023?

22nd Century Group's stock was trading at $0.9205 at the beginning of 2023. Since then, XXII shares have increased by 16.2% and is now trading at $1.07.
View the best growth stocks for 2023 here.

When is 22nd Century Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our XXII earnings forecast.

How were 22nd Century Group's earnings last quarter?

22nd Century Group, Inc. (NASDAQ:XXII) posted its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The biotechnology company had revenue of $19.38 million for the quarter, compared to analyst estimates of $19.63 million. 22nd Century Group had a negative trailing twelve-month return on equity of 49.37% and a negative net margin of 93.35%.

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include Aurora Cannabis (ACB), Alteryx (AYX), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Enphase Energy (ENPH), Inseego (INSG), Luckin Coffee (LKNCY), MediPharm Labs (MEDIF) and MercadoLibre (MELI).

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the NASDAQ under the ticker symbol "XXII."

Who are 22nd Century Group's major shareholders?

22nd Century Group's stock is owned by a variety of institutional and retail investors. Top institutional investors include International Assets Investment Management LLC (0.14%), Sigma Planning Corp (0.06%), AE Wealth Management LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Clifford B Fleet, James A Mish, John Franzino, Michael Zercher, Nora B Sullivan and Roger D O'brien.
View institutional ownership trends.

How do I buy shares of 22nd Century Group?

Shares of XXII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $1.07.

How much money does 22nd Century Group make?

22nd Century Group (NASDAQ:XXII) has a market capitalization of $230.37 million and generates $30.95 million in revenue each year. The biotechnology company earns $-32,610,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The official website for the company is www.xxiicentury.com. The biotechnology company can be reached via phone at (716) 270-1523, via email at investorrelations@xxiicentury.com, or via fax at 716-877-3064.

This page (NASDAQ:XXII) was last updated on 2/2/2023 by MarketBeat.com Staff